Exposome Assessment & Biomonitoring Protocol — Exposome
Comprehensive measurement of cumulative environmental exposure burden using blood/urine chemical panels, oxidative stress markers, allostatic load scoring, and environmental sensors.
Overview
The exposome — coined by Christopher Wild in 2005 — refers to the totality of environmental exposures from conception to death, and how those exposures interact with genetics to influence aging and disease. It is the environmental counterpart to the genome. Exposome-wide association studies (EWAS) are the environmental analog of GWAS, systematically linking exposures to health outcomes. Key measurement modalities include: GPL-TOX panel (Great Plains Laboratory) for environmental toxicants, heavy metal testing (blood, hair, urine challenge), mycotoxin urine testing, PFAS blood testing, total oxidative stress markers (8-OHdG, F2-isoprostanes, MDA), and allostatic load scoring (cumulative stress biomarkers across neuroendocrine, cardiovascular, metabolic, and immune systems). Emerging tools include home-based air quality monitors (Awair, PurpleAir), water quality testing, microplastic detection (not yet consumer-available), and wearable environmental sensors. Michael Snyder (Stanford) pioneered personal exposome tracking using multi-omics and wearables, demonstrating that individual exposure profiles vary dramatically even within the same household.
Indications
- Unexplained fatigue, cognitive decline, or multi-system symptoms
- Known environmental exposure history (occupational, residential)
- Baseline assessment for longevity optimization
- Pre- and post-intervention monitoring for detoxification protocols
- Accelerated biological age on epigenetic clock testing
- Chronic inflammatory markers without clear etiology
Mechanism of Action
The exposome framework recognizes that chronic low-dose exposure over decades may matter more than acute high-dose events — cumulative burden across chemical, physical, biological, and psychosocial domains drives biological age acceleration
Dosing
| Compound | Dose | Frequency | Notes |
|---|---|---|---|
| GPL-TOX Environmental Toxicant Panel | Urine sample collection | Baseline, then annually or post-intervention | Tests 172+ environmental pollutants including organophosphates, phthalates, benzene, xylene, vinyl chloride, pyrethrins, MTBE, perchlorate, acrolein |
| Heavy Metal Panel | Blood draw or 24-hour urine | Baseline, then every 6-12 months | Tests lead, mercury, arsenic, cadmium, aluminum, thallium; non-provoked preferred; Hair Elements Test as screening |
| Mycotoxin Panel | First morning urine | Baseline if mold-suspected; post-remediation | Tests ochratoxin A, aflatoxins, trichothecenes, gliotoxin, citrinin; correlate with ERMI home testing |
| Oxidative Stress Markers | Blood and urine | Every 6 months | 8-OHdG (DNA oxidation), F2-isoprostanes (lipid peroxidation), MDA (malondialdehyde) — composite oxidative burden score |
| Allostatic Load Panel | Comprehensive blood panel | Annually | Includes cortisol rhythm, DHEA-S, CRP, IL-6, fibrinogen, HbA1c, HDL, systolic BP, waist-hip ratio, IGF-1 — composite stress burden score |
Evidence Grade
GRADE C
Safety & Contraindications
- Provoked urine testing (chelation challenge) may overestimate body burden — non-provoked testing preferred by mainstream toxicology
- Over-testing without clinical context can lead to unnecessary anxiety and intervention
- Consumer-grade sensors provide directional data but may lack clinical-grade accuracy
- Allostatic load scoring requires comprehensive panel — partial panels may be misleading